X

Drug Profile

Research programme: anti-inflammatory therapeutics - Mestag Therapeutics/Merck

Latest Information Update: 25 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mestag Therapeutics
Developer Merck AG; Mestag Therapeutics
Class Anti-inflammatories; Antibodies
Mechanism of Action Fibroblast modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Inflammation

Most Recent Events

08 Oct 2024 Mestag Therapeutics and Merck enter into an option agreement to develop anti-inflammatory therapeutics
08 Oct 2024 Early research in Inflammation in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com